GHK-Cu and SSRIs (Sertraline, Escitalopram): Interaction Risk, Safety, and Clinical Guidance

What GHK-Cu Is and How It Works in the Body

GHK-Cu (glycyl-L-histidyl-L-lysine copper(II)) is a tripeptide-copper complex found naturally in human plasma, saliva, and urine. Plasma concentrations decline from roughly 200 ng/mL at age 20 to approximately 80 ng/mL by age 60 [1]. The peptide acts through multiple signaling cascades: it modulates TGF-β, VEGF, and several matrix metalloproteinases, which together promote wound healing, collagen synthesis, and anti-inflammatory activity [2].

GHK-Cu is used topically in cosmeceuticals and, increasingly, via subcutaneous injection through 503A compounding pharmacies for tissue repair and hair restoration research. Because it is a small peptide (molecular weight ~403 Da), its metabolism follows peptide hydrolysis pathways. Peptidases in plasma and tissue cleave GHK-Cu into its constituent amino acids and free copper. It does not circulate through the liver's cytochrome P450 system in any pharmacologically significant way [3]. This distinction matters because CYP-mediated metabolism is the most common site of drug-drug interactions.

The copper moiety released from GHK-Cu enters the body's existing copper homeostasis system, binding to ceruloplasmin, albumin, and metallothioneins [4]. Copper absorption, distribution, and excretion (primarily biliary) are tightly regulated by ATP7A and ATP7B transporters. This pathway is entirely separate from serotonergic neurotransmission or the metabolic routes of SSRIs.

How SSRIs Are Metabolized: Sertraline and Escitalopram

SSRIs inhibit serotonin reuptake at the presynaptic 5-HT transporter (SERT). Their interaction risk with other drugs comes from two sources: CYP enzyme inhibition and serotonergic pharmacodynamic overlap.

Sertraline is metabolized primarily by CYP2B6, with contributions from CYP2C19, CYP2C9, CYP3A4, and CYP2D6 [5]. At therapeutic doses (50 to 200 mg/day), sertraline is a mild inhibitor of CYP2D6. The FDA label warns about combinations with other serotonergic agents (triptans, MAOIs, tramadol) and drugs metabolized by CYP2D6 [6].

Escitalopram undergoes hepatic metabolism via CYP2C19 and CYP3A4, with a minor contribution from CYP2D6 [7]. It is a weaker CYP inhibitor than sertraline. The FDA prescribing information for Lexapro notes interactions with MAOIs, other serotonergic drugs, and CYP2C19 inhibitors like omeprazole, which can raise escitalopram plasma levels by approximately 50% [8].

Both drugs have well-characterized interaction profiles. The question is whether GHK-Cu shares any of these metabolic or receptor-level pathways. Based on available evidence, it does not.

Pharmacokinetic Interaction Analysis: Why CYP Overlap Is Absent

A drug-drug interaction at the pharmacokinetic level requires that two compounds share, inhibit, or induce the same metabolic enzymes or transporters. GHK-Cu does not meet any of these criteria with SSRIs.

GHK-Cu is a tripeptide. Peptides below approximately 40 amino acids are generally degraded by ubiquitous peptidases (aminopeptidases, carboxypeptidases, and endopeptidases) rather than by CYP450 isoenzymes [9]. No in vitro or in vivo study has demonstrated CYP2C19, CYP2D6, CYP3A4, or CYP2B6 involvement in GHK-Cu clearance. The peptide also lacks the structural characteristics (lipophilic aromatic rings, heteroatom-containing functional groups) that typically make a molecule a CYP substrate or inhibitor.

P-glycoprotein (P-gp/MDR1) and OATP transporters are another common site of interaction. Sertraline is a P-gp substrate [10]. GHK-Cu, however, has not been shown to interact with P-gp. Its molecular weight and hydrophilic peptide structure make P-gp-mediated efflux unlikely, though definitive transporter studies have not been published.

A reasonable clinical framework for assessing this combination: if the compound in question (GHK-Cu) does not enter the CYP system, does not bind P-gp, and does not affect serotonin reuptake or receptor activity, the standard mechanisms for SSRI drug-drug interactions are not engaged.

Pharmacodynamic Interaction Analysis: Serotonin Syndrome Risk

Serotonin syndrome is the primary pharmacodynamic concern when combining SSRIs with other agents. It occurs when excessive serotonergic activity accumulates at 5-HT1A and 5-HT2A receptors, producing a triad of neuromuscular excitability, autonomic instability, and altered mental status [11]. The Hunter Serotonin Toxicity Criteria require the presence of a serotonergic agent plus specific clinical findings (clonus, agitation, hyperthermia) for diagnosis [12].

GHK-Cu has no known activity at serotonin receptors. It does not inhibit serotonin reuptake, does not activate 5-HT receptor subtypes, and does not inhibit monoamine oxidase. A 2010 gene expression study using GHK-Cu on human fibroblasts found modulation of 4,048 genes at a significance threshold of P<0.05, but no genes in the serotonergic synthesis (TPH1, TPH2) or transport (SLC6A4) pathways were among them [13].

Copper itself is a cofactor for dopamine β-hydroxylase (DBH), which converts dopamine to norepinephrine. In Wilson disease, copper accumulation can produce psychiatric symptoms. But the copper delivered by standard GHK-Cu dosing (1 to 3 mg subcutaneously, containing roughly 0.16 to 0.48 mg of elemental copper) is trivial compared to normal daily dietary intake of 0.9 to 1.3 mg [14]. This dose would not meaningfully alter catecholamine synthesis or interact with SSRI pharmacodynamics.

Copper Homeostasis: The One Variable Worth Monitoring

While the interaction risk between GHK-Cu and SSRIs is low, copper homeostasis deserves attention for patients using injectable GHK-Cu over extended periods (months rather than weeks). This concern is independent of SSRI use.

Normal serum copper ranges from 70 to 140 µg/dL. Ceruloplasmin, the primary copper-carrying protein, accounts for 85 to 95% of circulating copper [15]. Excess free copper (not bound to ceruloplasmin) can generate reactive oxygen species through Fenton-type chemistry, contributing to oxidative stress in hepatocytes and neurons.

For patients on SSRIs who are also using GHK-Cu injections, a practical monitoring approach includes baseline serum copper and ceruloplasmin levels before starting GHK-Cu, with repeat testing at 3-month intervals during ongoing use. This is not because SSRIs alter copper metabolism. They do not. It is because any patient receiving exogenous copper should have periodic monitoring, and patients on psychiatric medications benefit from clinician oversight of their full supplement and peptide regimen.

One case-series consideration: SSRIs can mildly affect platelet function by reducing platelet serotonin content [16]. GHK-Cu promotes angiogenesis and tissue remodeling [2]. In theory, using both in the perioperative period could warrant discussion with a surgeon, not because of a direct interaction, but because both compounds touch vascular biology through independent mechanisms.

Topical GHK-Cu: An Even Lower Risk Profile

Most consumer exposure to GHK-Cu comes through topical serums and creams at concentrations of 0.01% to 1%. Systemic absorption of topically applied peptides is minimal due to the stratum corneum barrier and rapid peptidase degradation in the dermis [17].

A patient applying GHK-Cu serum to their face while taking sertraline 100 mg daily has, for all practical purposes, zero interaction risk. The amount of copper reaching systemic circulation from a topical peptide product is negligible. No dose adjustment, monitoring, or timing separation is warranted for topical use.

This contrasts with injectable or subcutaneous GHK-Cu, where systemic bioavailability is substantially higher and the copper delivery is more clinically relevant.

What Drug Interaction Databases Say

Major drug interaction databases (Lexicomp, Micromedex, Clinical Pharmacology) do not list GHK-Cu as a discrete entity. This absence reflects GHK-Cu's status as a research peptide compounded under FDA section 503A rather than an FDA-approved drug with a New Drug Application and formal interaction studies.

The absence of a listing does not confirm safety. It means no one has conducted and submitted the Phase I DDI studies that generate database entries. For FDA-approved SSRIs, interaction data are generated during development: in vitro CYP inhibition panels, clinical DDI studies with index substrates, and post-marketing pharmacovigilance. GHK-Cu has none of this infrastructure.

The practical implication: prescribers must reason from first principles (peptide metabolism, copper biology, serotonergic pharmacology) rather than relying on a database flag. The reasoning, as outlined in this article, suggests low risk.

Clinical Recommendations for Patients and Prescribers

For patients currently taking sertraline or escitalopram who want to use GHK-Cu, the following guidance reflects the available evidence and expert opinion:

Topical GHK-Cu: No precautions needed beyond standard cosmeceutical use. Continue SSRI dosing without modification.

Injectable/subcutaneous GHK-Cu (1 to 3 mg, 1 to 5 times per week): Inform your prescribing physician about SSRI use. No dose adjustment to either drug is expected to be necessary. Obtain baseline serum copper and ceruloplasmin. Repeat at 3 months.

Oral GHK-Cu supplements: Bioavailability data are limited. Copper content per capsule varies by manufacturer. If copper intake from GHK-Cu supplements plus diet exceeds the Tolerable Upper Intake Level of 10 mg/day [14], hepatotoxicity risk increases. This concern applies regardless of SSRI status.

Perioperative use: Discuss both GHK-Cu and SSRIs with the surgical team. SSRIs may increase bleeding risk through platelet serotonin depletion [16]. GHK-Cu promotes angiogenesis. Neither effect is large in isolation, but both touch hemostasis.

Reporting: Any unexpected symptom that arises after starting both agents should be reported to a physician. The FDA MedWatch system (for the SSRI) and direct prescriber communication (for the compounded peptide) are the appropriate channels.

Gaps in the Evidence and What Future Research Should Address

No randomized controlled trial has evaluated the concurrent use of GHK-Cu and any SSRI. No in vitro study has tested GHK-Cu against a standard CYP inhibition panel (the FDA-recommended battery using CYP1A2, 2B6, 2C8, 2C9, 2C19, 2D6, 3A4 substrates). No transporter study (P-gp, BCRP, OATP1B1/1B3, OAT1/3, OCT2) has been published for GHK-Cu.

These gaps do not necessarily indicate danger. They indicate that GHK-Cu remains in an early phase of clinical characterization. The peptide's biological properties (small size, rapid hydrolysis, endogenous origin, non-CYP metabolism) all point toward a low interaction potential, but "low probability based on mechanism" is not the same as "proven safe in a DDI trial."

A well-designed crossover pharmacokinetic study measuring sertraline AUC and Cmax with and without concurrent GHK-Cu dosing would resolve the question definitively. Until such data exist, clinical decisions must rely on mechanistic reasoning and patient-level monitoring.

Patients on SSRIs should not discontinue their antidepressant to "avoid an interaction" with GHK-Cu. The evidence does not support that decision. SSRI discontinuation carries its own risks, including discontinuation syndrome and depressive relapse, which are far better characterized than any theoretical GHK-Cu interaction [18].